Perioperative Effects of Radiological Contrast Agents

Classification of Contrast Agents

Radiological contrast agents fall into three main categories based on their chemical composition and clinical application:

Iodinated Contrast Media

Iodinated agents contain iodine atoms that absorb X-rays, creating radiographic contrast. These are classified by:

Osmolality:

• High-osmolar contrast media (HOCM): 1500-2000 mOsm/kg (approximately 5-8 times plasma osmolality of 285-295 mOsm/kg)
• Low-osmolar contrast media (LOCM): 600-800 mOsm/kg (approximately 2-3 times plasma osmolality)
• Iso-osmolar contrast media (IOCM): 290 mOsm/kg (equivalent to plasma)

Ionic structure:

• Ionic monomers (HOCM): diatrizoate, iothalamate
• Non-ionic monomers (LOCM): iopamidol, iohexol, iopromide
• Non-ionic dimers (IOCM): iodixanol

The trend toward LOCM and IOCM has significantly reduced adverse effects, though complications still occur.

Gadolinium-Based Agents

Used primarily for MRI, gadolinium chelates include:

• Linear chelates: gadopentetate dimeglumine, gadobenate dimeglumine
• Macrocyclic chelates: gadoterate meglumine, gadobutrol

Macrocyclic agents are more stable with lower risk of gadolinium dissociation.

Barium Sulphate

• An inert suspension used for gastrointestinal imaging.
• Though generally safe when contained within the GI tract, extravasation or aspiration carries significant risks.

Cardiovascular Effects

Haemodynamic Changes

Iodinated contrast media produce predictable cardiovascular effects through multiple mechanisms:

Direct myocardial depression:

• Negative inotropic effect through calcium channel interference
• More pronounced with HOCM than LOCM/IOCM
• Clinically significant in patients with ejection fraction <30%
• Transient reduction in systolic function lasting 10-20 minutes

Peripheral vasodilation:

• Immediate vasodilation following injection
• Mediated by endothelial nitric oxide release
• Transient hypotension (typically 10-20 mmHg systolic decrease)
• Compensatory tachycardia (10-20 bpm increase)
• More pronounced with HOCM due to higher osmolality

Volume effects:

• Osmotic load draws fluid into intravascular space
• Can precipitate pulmonary oedema in patients with limited cardiac reserve
• Volume expansion of approximately 10-15% occurs within minutes
• Risk particularly elevated when contrast volume exceeds 2-3 mL/kg

Arrhythmias

Electrocardiographic changes occur in 10-30% of patients receiving iodinated contrast:

• Sinus bradycardia (most common, vagally mediated)
• Ventricular ectopy
• Transient QT prolongation
• Rarely, ventricular tachycardia or fibrillation
• Risk factors include pre-existing cardiac disease and rapid bolus injection

Coronary Effects

Selective coronary angiography presents specific risks:

• Direct endothelial injury
• Coronary vasospasm (particularly with HOCM)
• Transient ST-segment changes in 5-10% of procedures
• Contrast-induced myocardial stunning

Renal Effects

Contrast-Induced Acute Kidney Injury (CI-AKI)

Defined as serum creatinine increase ≥44 μmol/L or ≥25% from baseline within 48-72 hours of contrast administration.

Pathophysiology involves:

• Direct tubular toxicity from reactive oxygen species
• Medullary hypoxia from altered renal haemodynamics
• Vasoconstriction of medullary vessels
• Tubular obstruction from contrast precipitation (especially with dehydration)

Incidence:

• General population: 1-2%
• Chronic kidney disease (eGFR <60): 10-20%
• Diabetes plus CKD: 20-30%
• Multiple risk factors: up to 50%

Risk factors include:

• Pre-existing renal impairment (most significant)
• Diabetes mellitus
• Dehydration
• Contrast volume >1.5 mL/kg or >300 mL total
• Multiple contrast studies within 72 hours
• Concurrent nephrotoxins (NSAIDs, aminoglycosides, ACE inhibitors)
• Heart failure
• Advanced age (>75 years)
• Anaemia
• Hypotension during procedure

Prevention strategies:

• Adequate hydration (isotonic saline 1 mL/kg/hr for 12 hours pre- and post-procedure)
• Minimizing contrast volume (use volume-to-creatinine clearance ratio <3)
• Withholding nephrotoxic medications
• Using iso-osmolar or low-osmolar agents
• Avoiding diuretics perioperatively
• Consider sodium bicarbonate infusion in high-risk patients (150 mL/hr for 6 hours)

N-acetylcysteine (600-1200 mg twice daily) remains controversial with conflicting evidence.

Hypersensitivity and Anaphylactoid Reactions

Classification of Reactions

Acute reactions (within 1 hour):

Mild (70-95% of reactions):

• Urticaria, pruritus
• Nausea, vomiting
• Flushing
• Metallic taste

Moderate (3-5%):

• Bronchospasm
• Facial oedema
• Vasovagal reactions
• Hypotension requiring treatment

Severe (<0.1%):

• Anaphylaxis
• Laryngeal oedema
• Cardiovascular collapse
• Loss of consciousness
• Seizures

Mechanisms

Most reactions are anaphylactoid (non-IgE mediated):

• Direct mast cell and basophil degranulation
• Complement activation
• Contact system activation
• Dose-independent
• Can occur on first exposure

True IgE-mediated anaphylaxis is rare but can occur with repeated exposures.

Risk Factors

• Previous reaction to contrast (strongest predictor: 17-35% recurrence risk)
• Asthma (5-fold increased risk)
• Allergy history
• Beta-blocker therapy (may mask symptoms and reduce adrenaline response)
• Mastocytosis
• Female gender
• Cardiovascular disease

Prophylaxis for High-Risk Patients

Standard regimen:

• Prednisolone 50 mg orally 13 hours, 7 hours, and 1 hour before procedure
• Plus antihistamine (H1 blocker: promethazine 25 mg or equivalent) 1 hour before
• Consider addition of H2 blocker (ranitidine 50 mg IV)

Alternative emergency protocol (when premedication not possible):

• Hydrocortisone 200 mg IV immediately
• Antihistamine IV
• Delay procedure 4-6 hours if feasible

Thyroid Effects

Iodine Load

Standard contrast CT delivers 15,000-30,000 μg of iodine (normal daily requirement 150 μg):

• Transient suppression of thyroid hormone synthesis (Wolff-Chaikoff effect)
• Usually resolves within weeks
• Risk of thyrotoxicosis in susceptible patients

Contrast-Induced Thyrotoxicosis

Occurs in patients with:

• Autonomous nodules
• Graves' disease in remission
• Iodine deficiency (paradoxically)
• Elderly patients in iodine-deficient regions

Manifestations:

• Onset typically 2-12 weeks post-exposure
• Atrial fibrillation
• Weight loss
• Tremor, anxiety
• Heart failure

Prevention:

• Screen high-risk patients (TSH measurement)
• Consider prophylactic thionamides in very high-risk patients
• Post-procedure monitoring in susceptible individuals

Neurological Effects

Contrast-Induced Encephalopathy

Rare complication characterized by:

• Confusion, altered consciousness
• Seizures (focal or generalized)
• Focal neurological deficits
• Cortical blindness
• Usually resolves within 24-72 hours

Risk factors:

• Disrupted blood-brain barrier (recent stroke, infection, hypertension)
• Renal impairment
• High contrast doses
• Intra-arterial cerebral injection

Mechanism:

• Blood-brain barrier disruption
• Direct neurotoxicity
• Osmotic effects causing oedema

Gadolinium Deposition

Recent recognition of gadolinium accumulation in:

• Deep brain nuclei (globus pallidus, dentate nucleus)
• Particularly with linear chelates
• Clinical significance uncertain
• No proven neurotoxicity in patients with normal renal function

Pulmonary Effects

Acute Pulmonary Reactions

Non-cardiogenic pulmonary oedema:

• Rare (<0.1%)
• Mechanism: increased capillary permeability
• Onset within minutes to hours
• Presents as acute respiratory distress

Bronchospasm:

• More common in asthmatics (4-8% vs 0.5% general population)
• Mediated by histamine and leukotriene release
• Usually occurs within 5 minutes
• Treat as acute asthma: bronchodilators, oxygen, steroids if severe

Aspiration of Barium

Catastrophic if barium enters airways:

• Chemical pneumonitis
• Acute respiratory distress syndrome
• Hypoxaemic respiratory failure
• Management: immediate bronchoscopy, supportive care
• High mortality (up to 50%)

Nephrogenic Systemic Fibrosis (NSF)

Rare but serious complication specific to gadolinium-based contrast in renal failure:

Risk factors:

• Severe renal impairment (eGFR <30 mL/min/1.73m²)
• Acute kidney injury
• Pro-inflammatory states
• Linear gadolinium chelates (greatest risk)

Clinical features:

• Progressive cutaneous fibrosis
• Joint contractures
• Scleroderma-like changes
• Internal organ fibrosis (heart, lungs, diaphragm)
• No effective treatment

Prevention:

• Avoid gadolinium if eGFR <30 unless absolutely necessary
• Use macrocyclic agents if required
• Consider haemodialysis immediately post-procedure (though efficacy uncertain)

Extravasation Injuries

Occurs in 0.1-0.9% of power injector administrations:

Manifestations:

• Local pain, swelling
• Skin blistering (with large volumes)
• Compartment syndrome (rare)
• Tissue necrosis (very rare, typically volumes >100 mL)

Management:

• Stop injection immediately
• Elevate affected limb
• Cold compresses for first 24 hours
• Surgical consultation if compartment syndrome suspected
• Most resolve spontaneously within days

Metformin Interaction

Metformin requires special consideration:

Traditional approach (now revised):

• Previous recommendation: withhold metformin for 48 hours post-contrast
• Rationale: fear of lactic acidosis if CI-AKI develops

Current evidence-based approach:

• Patients with eGFR ≥60: continue metformin
• Patients with eGFR 45-59: continue metformin, check creatinine 48 hours post-procedure
• Patients with eGFR 30-44: withhold metformin at time of procedure, check creatinine at 48 hours before restarting
• Patients with eGFR <30: contraindicated for contrast and metformin

Clinical Relevance

Preoperative Assessment

Anaesthetists must identify high-risk patients requiring:

• Alternative imaging modalities (ultrasound, non-contrast MRI)
• Prophylactic measures for allergic reactions
• Enhanced renal protective strategies
• Modification of perioperative medications

Risk stratification should include:

• Baseline renal function (measure eGFR)
• Previous contrast reactions
• Cardiac function assessment
• Volume status evaluation
• Medication review (nephrotoxins, metformin, beta-blockers)

Intraoperative Considerations

During procedures with contrast administration:

• Ensure adequate IV access separate from contrast injection site
• Maintain euvolaemia (guided by clinical assessment or monitoring)
• Monitor for acute reactions (anaphylaxis, bronchospasm)
• Have resuscitation drugs immediately available (adrenaline, bronchodilators)
• Consider invasive monitoring in high-risk cardiac patients
• Anticipate transient haemodynamic changes

Postoperative Monitoring

Implement appropriate surveillance:

• Serial renal function monitoring (baseline, 24-48 hours)
• Fluid balance documentation
• Recognition of delayed hypersensitivity reactions (up to 1 week)
• Assessment for volume overload in at-risk patients
• Neurological assessment if cerebral contrast used

Emergency Procedures

When contrast studies are urgent and cannot be delayed:

• Accept increased risk when benefits outweigh
• Implement maximum renal protection (hydration)
• Abbreviated allergic prophylaxis if history of reactions
• Prepare for management of complications
• Consider lower contrast volumes even if image quality compromised

Understanding these perioperative effects enables anaesthetists to optimize patient safety through risk stratification, preventive strategies, and prepared management of complications.